Bacterial Pneumonia in Patients with Sars-Cov-2 Omicron Infection: A Case Series A Case Series

Article Sidebar

PDF Download
Published Jul 6, 2023
DOI: https://doi.org/10.18103/mra.v11i7.1.4011

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Ryan M Gil
University of Utah
Lynn Keenan
University of Utah
Nathan Dean
University of Utah; Intermountain Health

Abstract

Recent SARS-coV-2 subvariants (BQ.1.1, BA.2, BA.4, BA.5, collectively referred to as Omicron) are adept at evading the immune system but tend to be less severe with fewer hospitalizations and deaths. The incidence of bacterial co-infection at time of admission for SARS-COV-2 related illness early in the COVID pandemic was low. In 2022 when few relatively healthy patients were being admitted, we report three patients found to have bacterial co-infection with pneumococcal and staphylococcal species at time of hospital admission. Varying practices abound, including use of procalcitonin as a screening tool for bacterial coinfection in patients with SARS-coV-2 infection despite a recommendation against this practice in recent pneumonia treatment guidelines.  In our cases the use of procalcitonin did not lead to antibiotic delay, however we propose a clinical support rule that can be utilized in the Emergency Department to more accurately guide empiric use of antibiotics in this patient population.

Keywords: Streptococcal pneumonia, Sars-Cov2, Staphylococcus, MSSA, co-infection, bacteremia

Article Details

How to Cite
GIL, Ryan M; KEENAN, Lynn; DEAN, Nathan. Bacterial Pneumonia in Patients with Sars-Cov-2 Omicron Infection: A Case Series. Medical Research Archives, [S.l.], v. 11, n. 7.1, july 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/4011>. Date accessed: 15 may 2024. doi: https://doi.org/10.18103/mra.v11i7.1.4011.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 11 No 7.1 (2023): July Issue, Vol.11, Issue 7.1
Section
Case Reports

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Johnson, A.G., et al., COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021. MMWR Morb Mortal Wkly Rep, 2022. 71(4): p. 132-138.
2. Strasser, Z.H., et al., Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England. JAMA Netw Open, 2022. 5(10): p. e2238354.
3. Ulloa, A.C., et al., Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. JAMA, 2022. 327(13): p. 1286-1288.
4. Vaughn, V.M., et al., Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study. Clin Infect Dis, 2021. 72(10): p. e533-e541.
5. Bhimraj, A., et al., Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis, 2022.
6. Kreitmann, L., et al., Early bacterial co-infection in ARDS related to COVID-19. Intensive Care Med, 2020. 46(9): p. 1787-1789.
7. Rouzé, A., et al., Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial. Am J Respir Crit Care Med, 2021. 204(5): p. 546-556.
8. Huang, D.T., et al., Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. N Engl J Med, 2018. 379(3): p. 236-249.
9. Brown, S.M., et al., Nonlinear Imputation of Pao2/Fio2 From Spo2/Fio2 Among Patients With Acute Respiratory Distress Syndrome. Chest, 2016. 150(2): p. 307-13.
10. Schuetz, P., et al., Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev, 2017. 10(10): p. CD007498.
11. Christ-Crain, M., et al., Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med, 2006. 174(1): p. 84-93.
12. Self, W.H., et al., Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia. Clin Infect Dis, 2018. 66(10): p. 1640-1641.
13. Kamat, I.S., et al., Low procalcitonin, community acquired pneumonia, and antibiotic therapy. Lancet Infect Dis, 2018. 18(5): p. 496-497.
14. Kamat, I.S., et al., Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis, 2020. 70(3): p. 538-542.
15. Metlay, J.P., et al., Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med, 2019. 200(7): p. e45-e67.
16. May, M., et al., Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019. Antimicrob Agents Chemother, 2021. 65(4).
17. Gautam, S., et al., Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia. Thorax, 2020. 75(11): p. 974-981.